<DOC>
	<DOCNO>NCT00056992</DOCNO>
	<brief_summary>Amino acid deprivation therapy effective mean treatment form cancer . Recently find human hepatocellular carcinoma ( HCC ) cell line appear require arginine growth . Arginine essential amino acid human adult infant synthesized citrulline ( review see Rogers 1994 ) . Therefore , selective elimination arginine circulation may mean treat patient metastatic melanoma non resectable HCC . The enzyme arginine deiminase ( ADI ) metabolize arginine citrulline ( Cunin 1986 ) . However , ADI find microbe human . ADI therefore , highly immunogenic short serum half-life follow injection . These potential drawback ( microbial source thus view foreign human immune system , short serum half-life ) overcome covalent attachment polyethylene glycol ( PEG ) argininedeiminase term drug ADI-PEG 20 . ADI-PEG 20 appear effective anti-cancer treatment human HCC . Pharmacokinetic pharmacodynamic data indicate week injection 160 IU/m2 ADI-PEG 20 eliminates detectable arginine circulation least 7 day . This treatment appear well tolerate . The purpose study determine efficacy treatment patient HCC . Efficacy primary end point study . No patient recieve placebo .</brief_summary>
	<brief_title>Testing ADI-PEG Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Histologically confirm diagnosis hepatocellular carcinoma . Nonresectable disease . Progressive disease chemotherapy , radiotherapy , surgery immunotherapy , long respond therapy , refuse therapy . Been previous treatment least 4 week . Been fully recover prior surgery . Age &gt; 18 year . Karnofsky performance status &gt; 70 . Expected survival &gt; 12 week . Total bilirubin &lt; 3.0 mg/dl . Serum albumin &gt; 3.0 g/dl . Serum SGOT &lt; 5 x upper limit normal . Serum alkaline phosphatase &lt; 5 x upper limit normal . Serum ammonia &lt; 55 mg/dl . Serum glucose &gt; 60 mg/dl . Serum amylase &lt; 1.5 x upper limit normal . ANC &gt; 1,500 / ml . Platelets &gt; 100,000 / ml . Female subject childbearing age male subject must ask use appropriate contraception male female duration study . Subjects must agree use two form contraception agree refrain intercourse duration study . Females must pregnant start study , serum HCG pregnancy test must negative entry study . Informed consent . Not enrol IND study . Disease must measurable evaluable .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2002</verification_date>
</DOC>